ArcanaBio announces new collaboration agreement with University Hospital of Iceland

Arcana approved by RSK to be allowed to offer Icelandic angel investors tax breaks on investment

ArcanaBio signs agreement with North Texas Genome Center, University of Texas Arlington

ArcanaBio secures 2nd grant from Sýklalyfjaónæmis- og súnusjóð to combat Antimicrobial Resistance

ArcanaBio's Rapid Saliva-Based COVID-19 Test Achieves 94.3% Sensitivity in Comparative Trial